There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (ONC – Research Report) and Embecta ...
Stocktwits on MSN8d
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of OptimismImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...
TipRanks on MSN4d
BeiGene Announces Share Options and RSUs GrantBeiGene Ltd ( ($HK:6160) ) has issued an announcement. BeiGene Ltd., a biopharmaceutical company, announced the grant of share options and ...
California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...
The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...
Two names immediately came to mind: BeiGene and Legend Biotech. The companies share some similarities. Although not named in the BIOSECURE legislation, both firms have deep China links ...
GlobalData on MSN7d
ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment comboImmunityBio has entered a supply agreement and partnership with BeiGene for conducting a confirmatory Phase III ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...
In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback